BRITISH MEDICAL JOURNAL 16 SEPTEMBER 1978 791 out of 25); the possible benefit of relatively high doses of asparaginase and cytosine arabinoside (cytarabine) given' early in UKALL I; and the relative merits of the different schedules of methotrexate and mercaptopurine. Journal, 1978, 2, 791-793 Summary and conclusions Thirty-nine adults with acute leukaemia who had relapsed when receiving extensive chemotherapy were treated with a combination of methotrexate and colaspase (L-asparaginase) given sequentially. Patients initially received 50-80 mg/M2 methotrexate, followed three hours later by intravenous colaspase, 40 000 lU/M2. Seven days later intravenous methotrexate, 120 mg/M2 was given. Each dose of methotrexate was followed 24 hours later by colaspase, and the two-day course of treatment was repeated every 7-14 days. The methotrexate dose was increased to tolerance by increments of 40 mg/M2 with each course, while the colaspase dose remained constant unless abnormal liver function developed, when it was reduced by half.
Summary and conclusions
Thirty-nine adults with acute leukaemia who had relapsed when receiving extensive chemotherapy were treated with a combination of methotrexate and colaspase (L-asparaginase) given sequentially. Patients initially received 50-80 mg/M2 methotrexate, followed three hours later by intravenous colaspase, 40 000 lU/M2. Seven days later intravenous methotrexate, 120 mg/M2 was given. Each dose of methotrexate was followed 24 hours later by colaspase, and the two-day course of treatment was repeated every 7-14 days. The methotrexate dose was increased to tolerance by increments of 40 mg/M2 with each course, while the colaspase dose remained constant unless abnormal liver function developed, when it was reduced by half.
Overall, 18 out of 39 patients achieved complete remission (46%). Of these, 13 out of 21 (62%) had acute lymphoblastic leukaemia, three out of seven (43%) acute undifferentiated leukaemia, and two out of 11 (18%) acute myeloblastic leukaemia. The median duration of complete remission was 20 weeks and the median duration of survival in complete responders was 45 weeks. The median number of courses needed to achieve complete remission was three. The maximum tolerated dose of methotrexate was 400 mg/M2 (median 200 Mg/m2).
Major side effects were due to colaspase. Methotrexate in doses of up to 400 mg/mi caused minimal myelosuppression and stomatitis, which suggested that colaspase Introduction Recently, several investigators have reported on the use of highdose methotrexate with folinic acid (citrovorum factor) rescue in patients with refractory acute leukaemias.'4 Nevertheless, the restriction of this regimen to centres with facilities for frequent monitoring of the patient to avoid severe toxicity and the enormous costs of the programme make it impracticable for widespread use. The combination of colaspase (L-asparaginase) and methotrexate may be synergistic or antagonistic, depending on the dose and type of schedule used. 
Results
Eighteen of the 39 patients (46%) achieved complete remission. The response rate was 62% (13/21) in acute lymphoblastic leukaemia, 43%0 (3/7) in acute undifferentiated leukaemia, and 18%o (2/11) in acute myeloblastic leukaemia. The median number of courses needed to achieve complete remission was three and the median number of days to achieve complete remission was 30. Of the 21 patients who failed to achieve complete remission, five died between three and 10 days after treatment was begun. Two patients had acute lymphoblastic leukaemia, two acute undifferentiated leukaemia, and one acute myeloblastic leukaemia. They all died from complications of previous treatment. If these five early deaths are excluded, with only the 34 patients who received an adequate trial being considered, the overall complete remission rate was 53% (18/34). The complete remission rate for patients with acute lymphoblastic leukaemia who had received an adequate trial was 68%/ (13/19), with acute undifferentiated leukaemia 60%/' (3/5) , and with acute myeloblastic leukaemia 20% (2/10).
The median duration of complete remission for all patients was 20 weeks (range 4-33 or more weeks) (fig 1) . The median survival time from the start of treatment for the responders was 45 weeks (range 15-55) and the median survival time of the patients who failed and who had received more than one course of treatment was nine weeks (range 2-26; P=0 002; see fig 2) . The number of previous induction regimens for the responders ranged from 1 to 8 (median 2) and from 1 to 5 (median 2) for the failures. The The major side effects were due to colaspase (table III) . Six patients had acute allergic reactions severe enough to require treatment. These six patients were later switched from E coli colaspase to Erwinia carotovora colaspase and had no hypersensitivity reactions with many subsequent courses. Transient depression of fibrinogen concentrations and raised liver-function values were often observed in early courses, but returned towards normal as treatment continued. Although two patients had abdominal pain, pancreatitis was not detected. Central nervous-system toxicity and haemorrhage from hypofibrinogenaemia were not observed. One patient had transient hyperglycaemia, and another developed disseminated herpes simplex during maintenance treatment, but was successfully treated with vidarabine (adenosine arabinoside). 
Discussion
The complete remission rate in our study for patients with acute lymphoblastic leukaemia is better than that achieved with other regimens used as secondary treatment"2 13 and is comparable with results of studies on previously untreated adult patients.14 15 Lister et al'4 recently reported a complete remission rate of 7100 (36/51) in the largest series of adults with previously untreated acute lymphoblastic leukaemia seen at one centre. Nine patients with acute lymphoblastic leukaemia or acute undifferentiated leukaemia had previously received conventional doses of methotrexate. The response rate in these patients was 670o, compared with 530o for patients who had not received methotrexate before. Among the nine patients who had received previous methotrexate treatment the response rate did not differ in those who were methotrexate resistant and those who were not-hence resistance to previous treatment with methotrexate in low dosage does not preclude subsequent response to our sequential combination.
High-dose methotrexate with folinic-acid rescue has been used with varying success in treating acute lymphoblastic leukaemia.1-4 Doses of between 80 and 240 mg/M2, in 24-hour infusion given every four days, achieved complete remission in three out of seven patients with acute lymphoblastic leukaemia, most of whom did not respond to conventional doses of methotrexate.' The median duration of remission was four months. Nevertheless, oral methotrexate in weekly doses of between 100 and 300 mg/M2 achieved no complete remissions in nine patients in another series.3 The use of colaspase as a rescue rather than folinic acid may be preferable, since colaspase is cytotoxic to leukaemic cells, but does not affect normal dividing cells. Our excellent results suggest possible therapeutic synergy between the two agents, and the minimal toxicity suggests that colaspase given sequentially provides relative protection from methotrexate toxicity. Several studies have also established the value of high-dose methotrexate in acute myeloblastic leukaemia, complete remission being achieved in one out of nine patients' and three out of 24 patients3 in different series. Our results in patients with acute myeloblastic leukaemia who had received extensive prior chemotherapy are comparable. Possibly better results might be obtained by combining this type of regimen with other drugs.
We found that the combination of sequential colaspase and methotrexate is highly effective in reinducing remission in adult patients with acute lymphoblastic leukaemia or acute undifferentiated leukaemia. The regimen was generally well tolerated, and excessive myelosuppression or other toxicity did not occur. Doses of methotrexate of up to 400 mg/M2 caused minimal myelosuppression and severe stomatitis was rarehence colaspase given sequentially seemed to confer adequate protection from toxicity and folinic-acid rescue was not needed. 
